The United States: the American Agency of medicine ( FDA) has to examine again on Thursday a request of marketing of the feminine "viagra.The American Agency of medicine ( FDA) has to examine again on Thursday a request of marketing of Flibanserin which, in case of green light, would be the first medicine doping the feminine libido on the market.
Two requests were already tapped again because of an efficiency considered very modest by comparison with the placebo. Besides, Flibanserin, intended for the non-menopausal women, produces non-unimportant side effects, especially nausea, intoxications and slumber.
The consultative committee of independent experts convened by the Food and Drug Administration ( FDA) will be entitled on Thursday to presentations of clinical trials and will understand testimonies of specialists and groups of defense of the women.
He will vote then at the end of the day to recommend or not for the apposition
That year, experts' consultative committee of the FDA had recommended the rejection of a skin patch of testosterone to dope the desire of the women finalized by Procter and Gamble. In 2011, a gelof testosterone for women press by Biohealth suffered a setback in clinical trials
Post a Comment